Sellas Life Sciences is expected to report a Q2 2026 net loss of $0.05 per share on zero revenue, with the stock currently trading at $12.01 against an average analyst price target of $27.50.
The single most critical factor for investors is an update on the progress of the pivotal Phase 3 REGAL trial for galinpepimut-S (GPS) in acute myeloid leukemia.
As of recent clinical updates, the trial was nearing the 80-event trigger required for final analysis, having recorded 78 events as of May. Shareholders are looking for confirmation that this milestone has been reached to support a regulatory filing and potential commercial launch in 2027.